Close

FBR Capital Starts Alexion Pharmaceuticals (ALXN) at Underperform; Sees 37% Downside

September 14, 2016 5:29 PM EDT Send to a Friend
FBR Capital initiates coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Underperform rating and a price target of $82.00, suggesting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login